Propanc Biopharma (PPCB) Osake Kurssi

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The company is headquartered in Melbourne, Victoria and currently employs 1 full-time employees. The company went IPO on 2012-06-15. The firm has developed a composite formulation of anti-cancer compounds, which together exert a range of effects designed to control or prevent tumors from recurring and spreading through the body. The firm's solution is to develop and commercialize a long-term therapy to prevent tumor recurrence and metastases. The company is developing pro-enzyme therapy for the treatment and prevention of the development of carcinomas from solid tumors. The firm's products include PRP and PRP-DCM. The firm's PRP is a formulation consisting of two pro-enzymes: trypsinogen and chymotrypsinogen, plus the enzyme amylase (1, 4-alpha-D-glucan glucanohydrolase). The pro-enzymes in PRP, typsinogen and chymotrypsinogen, exhibit specificity for tumor cells and not normal cells.